BALTIMORE, April 4, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("the Company") announced today that it has changed its name to Champions Oncology, Inc.
The name change reflects the Company's new strategic focus on developing advanced technologies to personalize the development and use of oncology drugs. As a result of this new focus, the Company does not currently plan to in-license any additional compounds in the future.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts™ , unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. The Company offers personalized Tumorgraft™ development, drug studies and genome sequencing as part of its Personalized Oncology Solutions ("POS") whereby physicians can evaluate the effects of cancer drugs on their patients' Tumorgrafts™ and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient. The Company's Tumorgraft™ Technology Platform is also used to provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) to leading pharmaceutical and biotechnology customers. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents and could lead to a faster and less expensive paths for drug development. TOS also includes biomarker discovery and the identification of novel drug combinations. In addition, the Company provides to oncologists and their patients expert tumor panels to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate.
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.
CHAMPIONS Oncology, Inc.
855 N. Wolfe Street, Suite 619
Baltimore, Maryland 21205 USA.
WEB SITE: www.championsoncology.com
|SOURCE Champions Oncology, Inc.|
Copyright©2010 PR Newswire.
All rights reserved